TPG Discloses 7.8% Stake in Odyssey Therapeutics, Including $25M Private Placement Post-IPO

summarizeSummary

TPG and its affiliates disclosed a 7.8% beneficial ownership stake in Odyssey Therapeutics, including a $25 million private placement at the IPO price, signaling strong institutional confidence post-IPO.

check_boxKey Events · Ownership and Investor Activity · ODTX

• Significant Stake Disclosure

  TPG GP A, LLC and its affiliates, including James G. Coulter and Jon Winkelried, disclosed a 7.8% beneficial ownership stake in Odyssey Therapeutics, totaling 3,690,146 shares.

• Private Placement Investment

  TPG Orazio II, an affiliate, completed a $25 million private placement on May 11, 2026, purchasing 1,388,889 shares at the IPO price of $18.00 per share.

• Substantial Institutional Backing

  The total beneficial ownership represents a substantial investment, valued at approximately $66.4 million based on the IPO price, indicating strong institutional confidence in the newly public company.

• Post-IPO Timing

  This filing follows the company's recent initial public offering on May 8, 2026, and provides details on a previously announced private placement, solidifying TPG's position as a major investor.

auto_awesomeAnalysis · ODTX · Life Sciences

This Schedule 13D filing reveals that TPG, a prominent investment firm, has taken a significant 7.8% stake in Odyssey Therapeutics. A key part of this stake includes a $25 million private placement completed at the IPO price, demonstrating TPG's confidence in the company's valuation and future prospects shortly after its public debut. This substantial investment from a major institutional player provides a strong vote of confidence for the newly public company.